Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
West Pharmaceutical Services, Inc. Common Stock
(NY:
WST
)
337.75
-2.22 (-0.65%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about West Pharmaceutical Services, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
1 of Wall Street’s Favorite Stocks for Long-Term Investors and 2 We Ignore
September 02, 2026
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Via
StockStory
Topics
Economy
1 Mid-Cap Stock on Our Buy List and 2 Facing Headwinds
September 01, 2026
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...
Via
StockStory
Topics
Economy
1 Healthcare Stock with Exciting Potential and 2 We Avoid
August 27, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...
Via
StockStory
Topics
Economy
3 Cash-Heavy Stocks We Approach with Caution
July 31, 2026
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...
Via
StockStory
Topics
Economy
West Pharmaceutical Services (NYSE:WST) Shows Explosive Potential with Perfect Minervini Trend Template and Accelerating Growth
↗
May 23, 2026
Via
Chartmill
3 Reasons to Avoid WST and 1 Stock to Buy Instead
July 31, 2026
West Pharmaceutical Services has been on fire lately. In the past six months alone, the company’s stock price has rocketed 43%, reaching $339.52 per share. T...
Via
StockStory
The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call
July 30, 2026
West Pharmaceutical Services posted a solid Q2, with revenue and adjusted earnings per share exceeding Wall Street expectations, while the market response re...
Via
StockStory
Topics
Earnings
Uncover the latest developments among S&P500 stocks in today's session.
↗
July 24, 2026
Via
Chartmill
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
July 24, 2026
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HC...
Via
StockStory
WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook
July 24, 2026
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 13....
Via
StockStory
West Pharmaceutical Services Q2 Earnings Call Highlights
↗
July 23, 2026
West Pharmaceutical Services (NYSE:WST) raised its full-year 2026 outlook after reporting second-quarter results that topped management’s expectations, supported by strong demand for high-value product...
Via
MarketBeat
Topics
Earnings
Full Transcript: West Pharmaceutical Servs Q2 2026 Earnings Call
↗
July 23, 2026
West Pharmaceutical Servs (NYSE:WST) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide...
Via
Benzinga
Topics
Earnings
These S&P500 stocks that are showing activity before the opening bell on Thursday.
↗
July 23, 2026
Via
Chartmill
West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars
July 23, 2026
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 13.8%...
Via
StockStory
Topics
Economy
West Pharmaceutical Services (WST) Q2 Earnings Report Preview: What To Look For
July 22, 2026
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be announcing earnings results tomorrow before market open. Here’s what to expect. W...
Via
StockStory
Topics
Artificial Intelligence
3 Reasons WST is Risky and 1 Stock to Buy Instead
July 13, 2026
Over the past six months, West Pharmaceutical Services has been a great trade, beating the S&P 500 by 21.8%. Its stock price has climbed to $353.68, represen...
Via
StockStory
Topics
Stocks
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)
July 07, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
Topics
Artificial Intelligence
Economy
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking Illumina (NASDAQ:ILMN)
July 06, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
Topics
Artificial Intelligence
Economy
1 High-Flying Stock Worth Your Attention and 2 Facing Challenges
June 25, 2026
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...
Via
StockStory
Topics
Economy
1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off
June 24, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via
StockStory
Topics
Economy
Top S&P500 movers in Tuesday's session
↗
June 09, 2026
Via
Chartmill
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
↗
June 09, 2026
Via
Chartmill
Q1 Rundown: UFP Technologies (NASDAQ:UFPT) Vs Other Drug Development Inputs & Services Stocks
June 08, 2026
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including UFP Technologies (NASDAQ:UFPT)...
Via
StockStory
3 Profitable Stocks with Open Questions
June 04, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via
StockStory
Topics
Economy
Billionaire Bill Gates' Foundation Dumped Microsoft but Loaded Up on This Dividend Champion
↗
June 02, 2026
The Microsoft founder's foundation recently added this healthcare stock to its portfolio.
Via
The Motley Fool
Q1 Earnings Highs And Lows: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks
June 01, 2026
Looking back on life sciences tools & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including PacBio (NASDAQ:PACB) and i...
Via
StockStory
Topics
Artificial Intelligence
Economy
Q1 Earnings Recap: West Pharmaceutical Services (NYSE:WST) Tops Drug Development Inputs & Services Stocks
May 20, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
Topics
Economy
Winners And Losers Of Q1: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services Stocks
May 19, 2026
Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Azenta (NASDAQ:AZTA) a...
Via
StockStory
1 S&P 500 Stock on Our Buy List and 2 Facing Headwinds
May 19, 2026
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Via
StockStory
Topics
Economy
Stocks
Drug Development Inputs & Services Stocks Q1 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers
May 17, 2026
Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Charles River Laborato...
Via
StockStory
Topics
Economy
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.